argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more
Market Cap & Net Worth: argenx SE (ARGNF)
argenx SE (OTCGREY:ARGNF) has a market capitalization of $43.16 Billion ($43.16 Billion) as of March 18, 2026. Listed on the OTCGREY stock exchange, this USA-based company holds position #500 globally and #402 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying argenx SE's stock price $697.42 by its total outstanding shares 61883406 (61.88 Million).
argenx SE Market Cap History: 2016 to 2025
argenx SE's market capitalization history from 2016 to 2025. Data shows growth from $965.55 Million to $43.16 Billion (56.39% CAGR).
argenx SE Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how argenx SE's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.85x
argenx SE's market cap is 14.85 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
39.04x
argenx SE's market cap is 39.04 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $965.55 Million | $17.15 Million | -$21.37 Million | 56.29x | N/A |
| 2017 | $3.20 Billion | $41.26 Million | -$28.08 Million | 77.62x | N/A |
| 2018 | $4.60 Billion | $29.23 Million | -$66.64 Million | 157.27x | N/A |
| 2019 | $7.94 Billion | $82.58 Million | -$162.97 Million | 96.10x | N/A |
| 2020 | $18.91 Billion | $44.80 Million | -$650.55 Million | 421.99x | N/A |
| 2021 | $18.88 Billion | $497.28 Million | -$408.26 Million | 37.96x | N/A |
| 2022 | $21.91 Billion | $410.75 Million | -$709.59 Million | 53.33x | N/A |
| 2023 | $22.96 Billion | $1.23 Billion | -$295.05 Million | 18.72x | N/A |
| 2024 | $32.53 Billion | $2.19 Billion | $833.04 Million | 14.85x | 39.04x |
Competitor Companies of ARGNF by Market Capitalization
Companies near argenx SE in the global market cap rankings as of March 18, 2026.
Key companies related to argenx SE by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): Ranked #507 globally with a market cap of $42.14 Billion USD.
- Argen-X (F:1AE): Ranked #552 globally with a market cap of $38.55 Billion USD ( €37.56 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #507 | Alnylam Pharmaceuticals Inc | NASDAQ:ALNY | $42.14 Billion | $318.91 |
| #552 | Argen-X | F:1AE | $38.55 Billion | €614.20 |
argenx SE Historical Marketcap From 2016 to 2025
Between 2016 and today, argenx SE's market cap moved from $965.55 Million to $ 43.16 Billion, with a yearly change of 56.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $43.16 Billion | +32.69% |
| 2024 | $32.53 Billion | +41.67% |
| 2023 | $22.96 Billion | +4.80% |
| 2022 | $21.91 Billion | +16.06% |
| 2021 | $18.88 Billion | -0.16% |
| 2020 | $18.91 Billion | +138.23% |
| 2019 | $7.94 Billion | +72.62% |
| 2018 | $4.60 Billion | +43.55% |
| 2017 | $3.20 Billion | +231.67% |
| 2016 | $965.55 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of argenx SE was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $43.16 Billion USD |
| MoneyControl | $43.16 Billion USD |
| MarketWatch | $43.16 Billion USD |
| marketcap.company | $43.16 Billion USD |
| Reuters | $43.16 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.